Nexvet is now part of Zoetis.
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly design monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, clinical development in the United States and Europe and is growing its biomanufacturing capabilities in Ireland.
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly design monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, clinical development in the United States and Europe and is growing its biomanufacturing capabilities in Ireland.
Location: Ireland, The Municipal District of Tullamore, Tullamore
Employees: 11-50
Total raised: $38.2M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Cthulhu Ve... | cthulhuven... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.04.2014 | Series B | $31.5M | - |
| 28.10.2013 | - | $6.7M | - |
Mentions in press and media 4
| Date | Title | Description |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 16.04.2014 | Nexvet Biopharma Closes US$31.5M Series B Financing | Nexvet Biopharma, a Melbourne, Australia-based veterinary biologic drug developer, closed a US$31.5m Series B round of financing. Backers included Farallon Capital Management, LLC, Adage Capital Partners, L.P, Foresite Capital, and Tavistoc... |
| 28.10.2013 | Nexvet Biopharma Raises AUD$7M in Capital | Nexvet Biopharma, a Melbourne, Australia-based veterinary monoclonal antibody drug developer, raised AUD$7m in capital. Backers included a range of new US investors, high net-worth individuals and Australian life sciences investment firm Bi... |
| 18.09.2012 | Veterinary start-up Nexvet seals $2.5 million seed round | An Australian veterinary medicine developer will use fresh funds to accelerate the clinical and business development of its drug portfolio, after completing a $2.5 million seed funding round. Nexvet Biopharma is developing specific medicine... |